Protocol EC-FV-01: A phase I study of EC145 administered in weeks 1 and 3 of a 4-week cycle

Trial Profile

Protocol EC-FV-01: A phase I study of EC145 administered in weeks 1 and 3 of a 4-week cycle

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Vintafolide (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Endocyte; Merck
  • Most Recent Events

    • 30 Sep 2008 Checked against clinicaltrials.gov record, added actual patient number.
    • 28 Jul 2008 Status changed from in progress to completed according to clinicaltrials.gov record.
    • 19 Jul 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top